Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNAPIST-III: Intracoronary Nanoparticle Paclitaxel for Restenosis
NCT00124943Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jul 2005
- Primary completion
- Aug 2009
- Modality
- Nanoparticles
01
Overview
Phase 2, randomised, open-label trial of Coroxane in coronary restenosis (4 arms), sponsored by Celgene Corporation. Primary endpoints: Number of Participants With Dose-limiting Toxicities at 1 week, Number of Participants With Procedural Complications at 24 hours and 2 more. Started Jul 2005; status: completed.
02
Drugs
Coroxane
03
Conditions
coronary restenosis
Beyond the preview
Go deeper on NCT00124943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124943.